首页> 外文OA文献 >PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

【2h】

PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

机译：在德国患有晚期或复发性非小细胞肺癌的患者中，与贝伐单抗+西西他汀和吉西他滨（BCG）联合西妥昔单抗+长春西汀和西西丁（CVC）的PCN41节省费用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Heigener D; Bischoff HG; Wiesner C; Aultman R;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC) [J] . S.Walzer, J.de Castro Carpeno, A.V.Vergnenegre, European Journal of Cancer Supplements . 2009,第2期

机译：9164贝伐单抗加顺铂和吉西他滨（BCG）或贝伐单抗加卡铂和紫杉醇（BCP）与培美曲塞加顺铂（PC）和西妥昔单抗加长春瑞滨和顺铂（CVC）的间接疗效比较非小细胞癌（NSCLC）
2. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG) [J] . Kotsakis A., Kentepozidis N., Emmanouilidis Ch., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第1期

机译：相较于多西他赛加顺铂和贝伐单抗方案，长春瑞滨加顺铂和贝伐单抗，多西他赛加吉西他滨和贝伐单抗的序贯给药作为晚期或转移性非鳞状非小细胞肺癌一线治疗的多西他赛方案希腊肿瘤研究小组（HORG）
3. 6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704 [J] . J.Bennouna, J.vonPawel, P.Zatloukal, European Journal of Cancer Supplements . 2007,第4期

机译：接受一线顺铂和吉西他滨联合贝伐单抗或安慰剂治疗的晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者的6509 ORAL口服高血压治疗（HTN）–来自III期随机试验BO17704的结果
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer [O] . Sevket Ozkaya, Serhat Findik, Oguz Uzun, 2008

机译：晚期非小细胞肺癌患者长春瑞滨-顺铂与吉西他滨-顺铂的比较
7. PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) [O] . Walzer S, de Castro Carpeño J, Vergnenegre A, 2009

机译：PCN14在患有癌或癌前病变的单发性癌患者中，贝伐单抗+西西他汀和吉西他滨（BCG）或贝伐单抗+卡铂和多西他塞（BCP）对比西妥昔单抗+长春瑞滨和西沙汀（CVC）在单发性癌前癌患者中的疗效差NSCLC）

PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

著录项

相似文献

相关主题

期刊订阅